(Q88117871)

English

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

scientific article published on 16 June 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

ChEBI release 2020-05-28

phase III clinical trial

1 reference

based on heuristic

inferred from title

0 references

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

Martin Ridderstråle

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Knut Robert Andersen

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Cordula Zeller

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Gabriel Kim

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Hans J Woerle

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Uli C Broedl

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

EMPA-REG H2H-SU trial investigators

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

publication date

16 June 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

The Lancet: Diabetes & Endocrinology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

691-700

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypoglycemia: minimizing its impact in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Metabolic effects of visceral fat accumulation in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-8587(14)70120-2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q88117871&oldid=1529010465"